Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AADACL2 antisense RNA 1 (AADACL2-AS1) is a human long non-coding RNA gene located on chromosome 3q25.1, overlapping and transcribed antisense to the AADACL2 protein-coding gene. This lncRNA is annotated across major gene databases (HGNC, Ensembl, NCBI, LNCipedia) with several transcript variants, most of which show no protein-coding potential[3][5][6][7][9]. Its biological functions and mechanistic impact are currently unknown; however, antisense lncRNAs are often hypothesized to regulate their corresponding sense gene (AADACL2) through transcriptional or post-transcriptional mechanisms. There is weak, indirect association with breast cancer, but no established role as a drug target, biomarker, or receptor, and no clinical safety or drug interaction data[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on AADACL2 antisense RNA 1 (AADACL2-AS1).